

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Tolvaptan for treating autosomal dominant polycystic kidney disease [ID652]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> • Otsuka Pharmaceuticals (tolvaptan) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • British Kidney Patient Association • Equalities National Council • Genetic Alliance UK • Jewish Genetic Disorders UK • Kidney Research UK • Muslim Council of Britain • Muslim Health Network • National Kidney Federation • PKD Charity • Rare Disease UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses and Counsellors • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Renal Society • British Society for Genetic Medicine • British Society for Histocompatibility and Immunogenetics • British Society for Human Genetics • British Transplantation Society • Clinical Molecular Genetics Society • ESPRIT • Renal Association • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Kidney Patients Association • Welsh Urological Society <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Renal Group • Department of Medical and Molecular Genetics, Kings College London • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Kleijnen Reviews • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre

<ul style="list-style-type: none"> • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Renal Pharmacy Group • United Kingdom Clinical Pharmacy Association • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Slough • NHS West Lancashire • Welsh Government 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that manufacture comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.